
Pyruvate kinase is a rate-limiting glycolytic enzyme. The PKM1 and PKM2 isoforms result from mutually exclusive alternative splicing of the PKM pre-mRNA. PKM2 rather than PKM1 regulates the Warburg effect and tumorigenesis by poorly understood mechanisms. Emerging evidence has revealed that ERK1/2 phosphorylates PKM2, but not PKM1, leading to PIN1-dependent cis-trans isomerization and conversion of PKM2 from a tetramer to a monomer. Monomeric PKM2 translocates into the nucleus, where it functions as a histone kinase and upregulates the expression of c-Myc and cyclin D1, thereby promoting the Warburg effect and cell cycle progression, respectively. Thus, nuclear PKM2 is essential for tumorigenesis and may serve as a target for treating human cancer.
Cell Nucleus, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Pyruvate Kinase, Cell Cycle Checkpoints, Up-Regulation, Histones, Proto-Oncogene Proteins c-myc, HEK293 Cells, Humans, Cyclin D1, Phosphorylation, Glycolysis
Cell Nucleus, Mitogen-Activated Protein Kinase 1, Mitogen-Activated Protein Kinase 3, Pyruvate Kinase, Cell Cycle Checkpoints, Up-Regulation, Histones, Proto-Oncogene Proteins c-myc, HEK293 Cells, Humans, Cyclin D1, Phosphorylation, Glycolysis
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 187 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Top 1% | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Top 10% | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Top 1% |
